Merit Cudkowicz, MD, MSc along with regimen co-lead Suma Babu, MBBS, MPH, of Massachusetts General Hospital and research scientists from Denali Therapeutics, presented the rationale and science behind DNL343, the investigational product being tested in Regimen G of the HEALEY ALS Platform Trial, and answered questions from the audience.
Visit the Mass General website to register for future webinars: www.massgeneral.org/neurology...
Sign up for the ALS Link to stay up to date about the Platform Trial and ALS research: lp.constantcontactpages.com/s...
Follow MGH Neurology on Facebook ( / mghneurology ) and Twitter ( / mghneurology )